Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
denovoSkin in Deep Partial and Full-thickness Burns
NCT06745557Phase 3Recruiting
- Sponsor
- CUTISS
- Start
- Dec 2024
- Primary completion
- Jun 2027
- Modality
- Implantable Devices, Implantable Hydrogels, Cell Therapies
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial of denovoSkin in burn injury (2 arms), sponsored by CUTISS. Primary endpoint: Composite endpoint of Wound closure and Scar quality (POSAS v2.0) at 6 months. Started Dec 2024; status: recruiting.
02
Drugs
denovoSkin
03
Conditions
burn injury
Beyond the preview
Go deeper on NCT06745557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06745557.